Exchange: NASDAQ·Updated 09:36 AM EST

TENK TenX Keane Acquisition

$0.5621
$0.0126
(2.29%)
Today
Mkt Cap$51.09M
Vol892.00

About TENK

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
58

Bullish Sentiment

How do you feel about TENK?

Advertisement|Remove ads.